Aileron-logo.png
Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements
30 nov. 2022 07h00 HE | Aileron Therapeutics, Inc.
BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more...
Aileron-logo.png
Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split
10 nov. 2022 08h00 HE | Aileron Therapeutics, Inc.
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more...
Aileron-logo.png
Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
01 nov. 2022 08h15 HE | Aileron Therapeutics, Inc.
Activated multiple existing and new sites under amended Phase 1b breast cancer clinical trial protocol; additional site activations anticipated in 4Q 2022 and 1Q 2023Presented healthy volunteer study...
Aileron-logo.png
Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference
26 oct. 2022 06h05 HE | Aileron Therapeutics, Inc.
p53-mediated cell cycle arrest results demonstrate potential of ALRN-6924 to prevent chemotherapy-induced neutropenia, thrombocytopenia, and anemia, as well as chemotherapy-induced alopecia (hair...
Aileron-logo.png
Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022
30 sept. 2022 08h41 HE | Aileron Therapeutics, Inc.
New ex vivo data demonstrates protection against cyclophosphamide-induced damage to hair follicles and their stem cellsEncore presentation of data presented at Society for Investigative Dermatology in...
Aileron-logo.png
Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference
22 sept. 2022 08h00 HE | Aileron Therapeutics, Inc.
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more...
Aileron-logo.png
Aileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
06 sept. 2022 07h00 HE | Aileron Therapeutics, Inc.
BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more...
Aileron-logo.png
Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
15 août 2022 16h15 HE | Aileron Therapeutics, Inc.
Company continues to advance ALRN-6924 as a selective chemoprotective agent for all patients with p53-mutated cancer, with immediate focus on breast cancer clinical trialExtended cash runway expected...
Aileron-logo.png
Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer
01 août 2022 07h51 HE | Aileron Therapeutics, Inc.
Enhancements to protocol, informed by recent ALRN-6924 data, are designed to improve the opportunity to demonstrate protection against chemotherapy-induced severe neutropenia, alopecia (hair loss) and...
Aileron-logo.png
Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022
08 juil. 2022 08h31 HE | Aileron Therapeutics, Inc.
BOSTON, July 08, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more...